Abstract
At its best, sequential analysis is an excellent means of obtaining dependable information quickly without prolonging a study more than is absolutely necessary; quite apart from a saving in time and expense this enables one to avoid exposing patients to an ineffective or second-rate form of treatment once it has become evident that another therapy is superior. The essential problem is how much further one can go along this road without leaving a degree of residual uncertainty as to the validity of the result obtained. The “look and see” or “not-very-sequential” approach, which enables the investigator to break the code as soon as a trend appears to be developing in one direction or the other, must clearly be used with some reticence where there are no urgent reasons to employ it, e.g. where the condition under treatment is not dangerous or seriously disabling and the importance of a reliable verdict (which will have repercussions for large patient populations) must weigh more heavily than the inconvenience suffered by those participants receiving the less-effective treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wardell, W.M., Velo, G. (1981). Sequential Analysis: Reply to the Presentations. In: Wardell, W.M., Velo, G. (eds) Drug Development, Regulatory Assessment, and Postmarketing Surveillance. NATO Advanced Study Institutes Series, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4055-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4055-3_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4057-7
Online ISBN: 978-1-4684-4055-3
eBook Packages: Springer Book Archive